Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 3 (2006), Issue 4 (April)

1. Recreational physical activity and sedentary behavior in relation to ovarian cancer risk in a large cohort of US women.
   Am J Epidemiol, 163(8): 709-16. [Abstract] [Full-text]
2. Prospective study of physical activity in different periods of life and the risk of ovarian cancer.
   Int J Cancer, 118(12): 3153-60. [Abstract] [Full-text]
3. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis.
   Int J Cancer, 118(12): 2981-90. [Abstract] [Full-text]
4. Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial.
   Br J Cancer, 94(7): 947-54. [Abstract] [Full-text]
5. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells.
   Endocrinology, 147(5): 2557-66. [Abstract] [Full-text]
6. Effect of a combination of extract from several plants on cell-mediated and humoral immunity of patients with advanced ovarian cancer.
   Phytother Res, 20(5): 424-5. [Abstract] [Full-text]
7. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
   Cancer, 106(9): 1933-9. [Abstract] [Full-text]
8. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma.
   Cancer, 106(9): 1925-32. [Abstract] [Full-text]
9. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.
   Cancer Treat Rev, 32(3): 180-90. [Abstract] [Full-text]
10. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.
    Scand J Immunol, 63(5): 355-64. [Abstract] [Full-text]
11. Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors.
    Oncogene, 25(18): 2636-45. [Abstract] [Full-text]
12. Involvement of Bcl-X(L) deamidation in E1A-mediated cisplatin sensitization of ovarian cancer cells.
    Oncogene, 25(18): 2656-65. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.